Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + fluorouracil + leucovorin + lenvatinib + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Hepatic Arterial Infusion, Oral, Intravenous
01
Overview
This combination therapy is an experimental first-line treatment regimen for advanced, unresectable, or metastatic intrahepatic cholangiocarcinoma (ICC). It utilizes Hepatic Arterial Infusion Chemotherapy (HAIC) to deliver a modified FOLFIRI-like regimen consisting of liposomal irinotecan, 5-fluorouracil, and leucovorin directly to the liver. This localized delivery is combined with the systemic administration of lenvatinib, an oral multikinase inhibitor, and an intravenous programmed cell death protein 1 (PD-1) inhibitor. The rationale behind this multi-modal approach is to leverage the local cytotoxic effects of HAIC, the anti-angiogenic and oncogenic signaling inhibition of lenvatinib, and the immune-potentiating effects of checkpoint inhibition to improve objective response rates and survival in patients with biliary tract cancers.
- Other names
- HAIC (liposomal irinotecan, 5-fluorouracil, leucovorin) + lenvatinib + PD-1 inhibitor
02
Targets
TOP1 (DNA Topoisomerase I)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on liposomal irinotecan + fluorouracil + leucovorin + lenvatinib + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + fluorouracil + leucovorin + lenvatinib + PD-1 inhibitor.